Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 109

1.

Six months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in ST-elevation myocardial infarction (DAPT-STEMI): randomised, multicentre, non-inferiority trial.

Kedhi E, Fabris E, van der Ent M, Buszman P, von Birgelen C, Roolvink V, Zurakowski A, Schotborgh CE, Hoorntje JCA, Eek CH, Cook S, Togni M, Meuwissen M, van Royen N, van Vliet R, Wedel H, Delewi R, Zijlstra F.

BMJ. 2018 Oct 2;363:k3793. doi: 10.1136/bmj.k3793.

2.

Multianalysis with optical coherence tomography and vasomotion in everolimus-eluting stents and everolimus-eluting biovascular scaffolds: the MOVES trial.

Arroyo DA, Schukraft S, Kallinikou Z, Stauffer JC, Baeriswyl G, Goy JJ, Togni M, Cook S, Puricel S.

Open Heart. 2018 Jan 3;5(1):e000624. doi: 10.1136/openhrt-2017-000624. eCollection 2018.

3.

Biodegradable Polymer Biolimus-Eluting Stents Versus Durable Polymer Everolimus-Eluting Stents in Patients With Coronary Artery Disease: Final 5-Year Report From the COMPARE II Trial (Abluminal Biodegradable Polymer Biolimus-Eluting Stent Versus Durable Polymer Everolimus-Eluting Stent).

Vlachojannis GJ, Smits PC, Hofma SH, Togni M, Vázquez N, Valdés M, Voudris V, Slagboom T, Goy JJ, den Heijer P, van der Ent M.

JACC Cardiovasc Interv. 2017 Jun 26;10(12):1215-1221. doi: 10.1016/j.jcin.2017.02.029. Epub 2017 May 31.

4.

Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds: Two-year clinical outcomes of the EVERBIO II trial.

Arroyo D, Gendre G, Schukraft S, Kallinikou Z, Müller O, Baeriswyl G, Stauffer JC, Goy JJ, Togni M, Cook S, Puricel S.

Int J Cardiol. 2017 Sep 15;243:121-125. doi: 10.1016/j.ijcard.2017.05.053. Epub 2017 May 12.

PMID:
28576627
5.

Deregulation of kinase signaling and lymphoid development in EBF1-PDGFRB ALL leukemogenesis.

Welsh SJ, Churchman ML, Togni M, Mullighan CG, Hagman J.

Leukemia. 2018 Jan;32(1):38-48. doi: 10.1038/leu.2017.166. Epub 2017 May 30.

6.

Transcutaneous aortic valve implantation using the carotid artery access: Feasibility and clinical outcomes.

Kallinikou Z, Berger A, Ruchat P, Khatchatourov G, Fleisch I, Korkodelovic B, Henchoz E, Marti RA, Cook S, Togni M, Goy JJ.

Arch Cardiovasc Dis. 2017 Jun - Jul;110(6-7):389-394. doi: 10.1016/j.acvd.2016.10.005. Epub 2017 Apr 19.

7.

NUP98-fusion transcripts characterize different biological entities within acute myeloid leukemia: a report from the AIEOP-AML group.

Bisio V, Zampini M, Tregnago C, Manara E, Salsi V, Di Meglio A, Masetti R, Togni M, Di Giacomo D, Minuzzo S, Leszl A, Zappavigna V, Rondelli R, Mecucci C, Pession A, Locatelli F, Basso G, Pigazzi M.

Leukemia. 2017 Apr;31(4):974-977. doi: 10.1038/leu.2016.361. Epub 2016 Nov 28. No abstract available.

PMID:
27890935
8.

Genomic complexity and dynamics of clonal evolution in childhood acute myeloid leukemia studied with whole-exome sequencing.

Masetti R, Castelli I, Astolfi A, Bertuccio SN, Indio V, Togni M, Belotti T, Serravalle S, Tarantino G, Zecca M, Pigazzi M, Basso G, Pession A, Locatelli F.

Oncotarget. 2016 Aug 30;7(35):56746-56757. doi: 10.18632/oncotarget.10778.

9.

Radiation Exposure of the Operator During Coronary Interventions (from the RADIO Study).

Kallinikou Z, Puricel SG, Ryckx N, Togni M, Baeriswyl G, Stauffer JC, Cook S, Verdun FR, Goy JJ.

Am J Cardiol. 2016 Jul 15;118(2):188-94. doi: 10.1016/j.amjcard.2016.04.045. Epub 2016 May 5.

PMID:
27239022
10.

Heart rate never lies: interventional cardiologist and Braude's quote revised.

Cook S, Stauffer JC, Goy JJ, Graf D, Puricel S, Frobert A, Muller O, Togni M, Arroyo D.

Open Heart. 2016 Jan 11;3(1):e000373. doi: 10.1136/openhrt-2015-000373. eCollection 2016.

11.

Vascular response to everolimus- and biolimus-eluting coronary stents versus everolimus-eluting bioresorbable scaffolds--an optical coherence tomography substudy of the EVERBIO II trial.

Kallinikou Z, Arroyo D, Togni M, Lehman S, Corpataux N, Cook M, Müller O, Baeriswyl G, Stauffer JC, Goy JJ, Puricel SG, Cook S.

Swiss Med Wkly. 2016 Jan 14;146:w14274. doi: 10.4414/smw.2016.14274. eCollection 2016.

12.

Comparison of endothelium-dependent and -independent vasomotor response after abluminal biodegradable polymer biolimus-eluting stent and persistent polymer everolimus-eluting stent implantation (COMPARE-IT).

Puricel S, Kallinikou Z, Espinola J, Arroyo D, Goy JJ, Stauffer JC, Baeriswyl G, Smits PC, Cook S, Togni M.

Int J Cardiol. 2016 Jan 1;202:525-31. doi: 10.1016/j.ijcard.2015.09.085. Epub 2015 Sep 26.

PMID:
26440470
13.
14.

Identification of the NUP98-PHF23 fusion gene in pediatric cytogenetically normal acute myeloid leukemia by whole-transcriptome sequencing.

Togni M, Masetti R, Pigazzi M, Astolfi A, Zama D, Indio V, Serravalle S, Manara E, Bisio V, Rizzari C, Basso G, Pession A, Locatelli F.

J Hematol Oncol. 2015 Jun 12;8:69. doi: 10.1186/s13045-015-0167-8.

15.

The adhesion- and degranulation-promoting adaptor protein and its role in the modulation of experimental autoimmune encephalomyelitis.

Engelmann S, Togni M, Kliche S, Reinhold D, Schraven B, Reinhold A.

Crit Rev Immunol. 2015;35(1):1-14. Review.

PMID:
25746044
16.

Comparison of everolimus- and biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds.

Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, Muller O, Allard L, Stauffer JC, Togni M, Goy JJ, Cook S.

J Am Coll Cardiol. 2015 Mar 3;65(8):791-801. doi: 10.1016/j.jacc.2014.12.017.

17.

[Thoughts on a regional or national single-payer system in Switzerland].

Togni M.

Rev Med Suisse. 2014 Oct 8;10(445):1895. French. No abstract available.

PMID:
25417368
18.

A case of hyperemesis in bulimia nervosa.

Pedrolli C, Sacchi MC, Togni M, Cereda E.

Int J Eat Disord. 2015 May;48(4):446-8. doi: 10.1002/eat.22315. Epub 2014 Jun 5.

PMID:
24902945
19.

Ten-year clinical follow-up after sirolimus-eluting stent implantation.

Palhais N, Arroyo D, Lehmann S, Togni M, Kaufmann U, Puricel SG, Stauffer JC, Goy JJ, Cook S.

Am Heart J. 2014 Jun;167(6):893-9. doi: 10.1016/j.ahj.2013.12.013. Epub 2014 Jan 4.

PMID:
24890540
20.

Infants with acute myeloid leukemia treated according to the Associazione Italiana di Ematologia e Oncologia Pediatrica 2002/01 protocol have an outcome comparable to that of older children.

Masetti R, Rondelli R, Fagioli F, Mastronuzzi A, Pierani P, Togni M, Menna G, Pigazzi M, Putti MC, Basso G, Pession A, Locatelli F.

Haematologica. 2014 Aug;99(8):e127-9. doi: 10.3324/haematol.2014.106526. Epub 2014 May 16. No abstract available.

21.

A propensity score-matched comparison between Cardia and Amplatzer PFO closure devices - insights from the SOLUTION registry (Swiss percutaneOus patent foramen ovale cLosUre in recurrent clinical events prevenTION).

Puricel S, Arroyo D, Goy JJ, Praz F, Palhais N, Wahl A, Stauffer JC, Togni M, Berger A, Meier B, Cook S.

EuroIntervention. 2015 Jun;11(2):230-7. doi: 10.4244/EIJY14M05_05.

22.

Whole transcriptome sequencing of a paediatric case of de novo acute myeloid leukaemia with del(5q) reveals RUNX1-USP42 and PRDM16-SKI fusion transcripts.

Masetti R, Togni M, Astolfi A, Pigazzi M, Indio V, Rivalta B, Manara E, Rutella S, Basso G, Pession A, Locatelli F.

Br J Haematol. 2014 Aug;166(3):449-52. doi: 10.1111/bjh.12855. Epub 2014 Mar 27. Review. No abstract available.

PMID:
24673627
23.

Comparison of everolimus-eluting and biolimus-eluting coronary stents with everolimus-eluting bioresorbable scaffold: study protocol of the randomized controlled EVERBIO II trial.

Arroyo D, Togni M, Puricel S, Gerard B, Sonja L, Corpataux N, Villeneuve H, Boute E, Stauffer JC, Goy JJ, Cook S.

Trials. 2014 Jan 7;15:9. doi: 10.1186/1745-6215-15-9.

24.

MYCN is a novel oncogenic target in pediatric T-cell acute lymphoblastic leukemia.

Astolfi A, Vendemini F, Urbini M, Melchionda F, Masetti R, Franzoni M, Libri V, Serravalle S, Togni M, Paone G, Montemurro L, Bressanin D, Chiarini F, Martelli AM, Tonelli R, Pession A.

Oncotarget. 2014 Jan 15;5(1):120-30.

25.

DHH-RHEBL1 fusion transcript: a novel recurrent feature in the new landscape of pediatric CBFA2T3-GLIS2-positive acute myeloid leukemia.

Masetti R, Togni M, Astolfi A, Pigazzi M, Manara E, Indio V, Rizzari C, Rutella S, Basso G, Pession A, Locatelli F.

Oncotarget. 2013 Oct;4(10):1712-20.

26.

T cell-independent modulation of experimental autoimmune encephalomyelitis in ADAP-deficient mice.

Engelmann S, Togni M, Thielitz A, Reichardt P, Kliche S, Reinhold D, Schraven B, Reinhold A.

J Immunol. 2013 Nov 15;191(10):4950-9. doi: 10.4049/jimmunol.1203340. Epub 2013 Oct 7.

27.

Urinary Neutrophil Gelatinase-Associated Lipocalin (uNGAL) and contrast-induced acute kidney injury after coronary angiogram.

Perrin T, Descombes E, Magnin JL, Gachet M, Hemett OM, Hayoz D, Stolt V, Baeriswyl G, Stauffer JC, Goy JJ, Togni M, Cook S.

Swiss Med Wkly. 2013 Aug 27;143:w13853. doi: 10.4414/smw.2013.13853. eCollection 2013.

28.

Acute coronary syndrome in patients younger than 30 years--aetiologies, baseline characteristics and long-term clinical outcome.

Puricel S, Lehner C, Oberhänsli M, Rutz T, Togni M, Stadelmann M, Moschovitis A, Meier B, Wenaweser P, Windecker S, Stauffer JC, Cook S.

Swiss Med Wkly. 2013 Jul 29;143:w13816. doi: 10.4414/smw.2013.13816. eCollection 2013.

29.

How should I treat a left main spontaneous dissection involving left anterior descending artery, intermediate branch artery and left circumflex artery?

Bernelli C, Ajello S, Piraino D, Chieffo A, Montorfano M, Maccagni D, Durante A, Sacco FM, Margonato A, Colombo A, Cook S, Togni M, Voskuil M, Stella P.

EuroIntervention. 2013 Jun 22;9(2):285-9. doi: 10.4244/EIJV9I2A45.

30.

Long-term comparison of everolimus-eluting and biolimus-eluting stents.

Puricel S, Oberhänsli M, Guntern P, Lehmann S, Goy JJ, Arroyo D, Villeneuve H, Baeriswyl G, Stauffer JC, Togni M, Cook S.

EuroIntervention. 2013 Jul;9(3):336-44. doi: 10.4244/EIJV9I3A55.

31.

CBFA2T3-GLIS2 fusion transcript is a novel common feature in pediatric, cytogenetically normal AML, not restricted to FAB M7 subtype.

Masetti R, Pigazzi M, Togni M, Astolfi A, Indio V, Manara E, Casadio R, Pession A, Basso G, Locatelli F.

Blood. 2013 Apr 25;121(17):3469-72. doi: 10.1182/blood-2012-11-469825. Epub 2013 Feb 13.

PMID:
23407549
32.

Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.

Smits PC, Hofma S, Togni M, Vázquez N, Valdés M, Voudris V, Slagboom T, Goy JJ, Vuillomenet A, Serra A, Nouche RT, den Heijer P, van der Ent M.

Lancet. 2013 Feb 23;381(9867):651-60. doi: 10.1016/S0140-6736(12)61852-2. Epub 2013 Jan 30.

PMID:
23374650
33.

A modified technique of balloon anchoring for tricky stent delivery.

Aeby G, Surmely JF, Togni M, Cook S.

EuroIntervention. 2013 Jan 22;8(9):1099-102. doi: 10.4244/EIJV8I9A168. No abstract available.

34.
35.

A randomized comparison of platelet reactivity in patients after treatment with various commercial clopidogrel preparations: the CLO-CLO trial.

Oberhänsli M, Lehner C, Puricel S, Lehmann S, Togni M, Stauffer JC, Baeriswyl G, Goy JJ, Cook S.

Arch Cardiovasc Dis. 2012 Nov;105(11):587-92. doi: 10.1016/j.acvd.2012.06.001. Epub 2012 Oct 4.

36.

Optical coherence tomography findings in renal denervation.

Cook S, Goy JJ, Togni M.

Eur Heart J. 2012 Dec;33(23):2992. doi: 10.1093/eurheartj/ehs201. Epub 2012 Sep 26. No abstract available.

PMID:
23014864
37.

Vascular scaffolding to seal giant aneurysms: a new technique.

Goy JJ, Togni M, Cook S.

Heart. 2012 Nov;98(22):1681-2. doi: 10.1136/heartjnl-2012-302199. Epub 2012 Jul 18. No abstract available.

PMID:
22810852
38.

The adapter protein ADAP is required for selected dendritic cell functions.

Togni M, Engelmann S, Reinhold D, Schraven B, Reinhold A.

Cell Commun Signal. 2012 Jun 6;10(1):14. doi: 10.1186/1478-811X-10-14.

39.

Impact of incomplete stent apposition on long-term clinical outcome after drug-eluting stent implantation.

Cook S, Eshtehardi P, Kalesan B, Räber L, Wenaweser P, Togni M, Moschovitis A, Vogel R, Seiler C, Eberli FR, Lüscher T, Meier B, Jüni P, Windecker S.

Eur Heart J. 2012 Jun;33(11):1334-43. doi: 10.1093/eurheartj/ehr484. Epub 2012 Jan 26.

40.

CCR7-mediated LFA-1 functions in T cells are regulated by 2 independent ADAP/SKAP55 modules.

Kliche S, Worbs T, Wang X, Degen J, Patzak I, Meineke B, Togni M, Moser M, Reinhold A, Kiefer F, Freund C, Förster R, Schraven B.

Blood. 2012 Jan 19;119(3):777-85. doi: 10.1182/blood-2011-06-362269. Epub 2011 Nov 23.

PMID:
22117043
41.

Patent foramen ovale: a culpable pathway for myocardial infarction.

Stortecky S, Cook S, Meier B, Togni M.

J Am Coll Cardiol. 2011 Oct 25;58(18):1923. doi: 10.1016/j.jacc.2011.01.078. No abstract available.

42.

Clinical outcomes after PCI for acute coronary syndrome in unprotected left main coronary artery disease: insights from the Swiss Acute Left Main Coronary Vessel Percutaneous Management (SALVage) study.

Puricel S, Adorjan P, Oberhänsli M, Stauffer JC, Moschovitis A, Vogel R, Goy JJ, Müller O, Eeckhout E, Togni M, Wenaweser P, Meier B, Windecker S, Cook S.

EuroIntervention. 2011 Oct 30;7(6):697-704. doi: 10.4244/EIJV7I6A112.

43.

Comparison of titanium-nitride-oxide-coated stents with zotarolimus-eluting stents for coronary revascularization a randomized controlled trial.

Pilgrim T, Räber L, Limacher A, Löffel L, Wenaweser P, Cook S, Stauffer JC, Togni M, Vogel R, Garachemani A, Moschovitis A, Khattab AA, Seiler C, Meier B, Jüni P, Windecker S.

JACC Cardiovasc Interv. 2011 Jun;4(6):672-82. doi: 10.1016/j.jcin.2011.02.017.

44.

Five-year clinical and angiographic outcomes of a randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial.

Räber L, Wohlwend L, Wigger M, Togni M, Wandel S, Wenaweser P, Cook S, Moschovitis A, Vogel R, Kalesan B, Seiler C, Eberli F, Lüscher TF, Meier B, Jüni P, Windecker S.

Circulation. 2011 Jun 21;123(24):2819-28, 6 p following 2828. doi: 10.1161/CIRCULATIONAHA.110.004762. Epub 2011 Jun 6.

PMID:
21646500
45.

Long-term comparison of everolimus-eluting and sirolimus-eluting stents for coronary revascularization.

Räber L, Jüni P, Nüesch E, Kalesan B, Wenaweser P, Moschovitis A, Khattab AA, Bahlo M, Togni M, Cook S, Vogel R, Seiler C, Meier B, Windecker S.

J Am Coll Cardiol. 2011 May 24;57(21):2143-51. doi: 10.1016/j.jacc.2011.01.023.

46.

[Coronary stent thrombosis: what's new in 2011?].

Oberhänsli M, Puricel S, Togni M, Cook S.

Herz. 2011 May;36(3):241-53. doi: 10.1007/s00059-011-3464-1. German.

PMID:
21505933
47.

Colonoscopic findings in first-degree relatives of patients with colorectal cancer: a population-based screening program.

Armelao F, Paternolli C, Franceschini G, Franch R, Orlandi PG, Miori G, Avancini I, Togni M, Rossi M, Meggio A, Tasini E, Manfrini R, Giacomin D, Fasoli R, Faitini K, Mastromauro M, Costa S, Ridolfi F, Rosi P, de Pretis G.

Gastrointest Endosc. 2011 Mar;73(3):527-534.e2. doi: 10.1016/j.gie.2010.12.025.

PMID:
21353850
48.

[Acute myocardial infarction: importance of the networking in the initial management].

Oberhänsli M, Stauffer JC, Togni M, Ribordy V, Chabanel D, Hayoz D, Cook S.

Rev Med Suisse. 2010 Nov 17;6(271):2166, 2168-72. French.

PMID:
21155290
49.

Impact of arterial injury on neointimal hyperplasia after implantation of drug-eluting stents in coronary arteries: an intravascular ultrasound study.

Eshtehardi P, Cook S, Wandel S, Räber L, Wenaweser P, Togni M, Vogel R, Garachemani A, Eberli FR, Lüscher TF, Jüni P, Hess OM, Meier B, Windecker S.

EuroIntervention. 2010 Sep;6(4):467-74. doi: 10.4244/EIJ30V6I4A79.

50.

Instantaneous coronary collateral function during supine bicycle exercise.

Togni M, Gloekler S, Meier P, de Marchi SF, Rutz T, Steck H, Traupe T, Seiler C.

Eur Heart J. 2010 Sep;31(17):2148-55. doi: 10.1093/eurheartj/ehq202. Epub 2010 Jun 28.

Supplemental Content

Support Center